Drug intelligence / Profile preview

LPI-1503

Development stage: Phase 1
Lead developer: Luxena Pharmaceuticals
Modality: Small Molecules
Administration: Inhalation

Overview

LPI-1503 is a novel dry powder inhalation formulation of ondansetron, a selective 5-HT3 receptor antagonist, being developed by Luxena Pharmaceuticals. It is designed for the prevention and treatment of postoperative nausea and vomiting (PONV), as well as chemotherapy-induced (CINV) and radiation-induced nausea and vomiting (RINV). By utilizing pulmonary delivery via a novel aerosol formulation, LPI-1503 aims to provide a faster onset of action and a non-invasive alternative to traditional intravenous or oral administration. The drug is delivered using a single-capsule inhaler (RS01), allowing for rapid systemic absorption through the lungs to block serotonin-mediated emetic signals.

Other names: Ondansetron Inhalation Powder

Targets

HTR3A (5-hydroxytryptamine receptor 3A)

Beyond the preview

Go deeper on LPI-1503.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on LPI-1503.

Explore the full profile